688520 Stock Overview
A biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Sinocelltech Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥39.30 |
| 52 Week High | CN¥56.50 |
| 52 Week Low | CN¥31.07 |
| Beta | 0.63 |
| 11 Month Change | 7.91% |
| 3 Month Change | 9.65% |
| 1 Year Change | -22.79% |
| 33 Year Change | -28.25% |
| 5 Year Change | n/a |
| Change since IPO | -46.22% |
Recent News & Updates
Shareholder Returns
| 688520 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.5% | -4.3% | -3.9% |
| 1Y | -22.8% | -17.7% | 4.0% |
Return vs Industry: 688520 underperformed the CN Biotechs industry which returned -14.2% over the past year.
Return vs Market: 688520 underperformed the CN Market which returned 6.7% over the past year.
Price Volatility
| 688520 volatility | |
|---|---|
| 688520 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.4% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 688520 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688520's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,348 | Liangzhi Xie | www.sinocelltech.com |
Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China. The company offers AnpingxiA (repertuzumab injection), an anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E. Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of solid tumors; SCT-I10A, a monoclonal antibody injection which is in phase 3 trials for the treatment of solid tumors; SCTV01, a new generation vaccine which is in phase 3 trials for the treatment of corona virus; SCT510 for the treatment of solid tumors; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000, which is in phase 3 clinical trials for the treatment of human papillomavirus, as well as SCTA01 which is in phase 2/3 clinical research trials for the treatment of SARS COV-2.
Sinocelltech Group Limited Fundamentals Summary
| 688520 fundamental statistics | |
|---|---|
| Market cap | CN¥17.50b |
| Earnings (TTM) | -CN¥26.10m |
| Revenue (TTM) | CN¥2.45b |
7.2x
P/S Ratio-670.6x
P/E RatioIs 688520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688520 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.45b |
| Cost of Revenue | CN¥139.01m |
| Gross Profit | CN¥2.31b |
| Other Expenses | CN¥2.33b |
| Earnings | -CN¥26.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 94.31% |
| Net Profit Margin | -1.07% |
| Debt/Equity Ratio | -1,974.4% |
How did 688520 perform over the long term?
See historical performance and comparison